BRENDA home
History
Information on EC 1.3.1.9 - enoyl-[acyl-carrier-protein] reductase (NADH)
for references in articles please use BRENDA:EC1.3.1.9Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
1.3.1.9 enoyl-[acyl-carrier-protein] reductase (NADH)IUBMB Comments
The enzyme catalyses an essential step in fatty acid biosynthesis, the reduction of the 2,3-double bond in enoyl-acyl-[acyl-carrier-protein] derivatives of the elongating fatty acid moiety. The enzyme from the bacterium Escherichia coli accepts substrates with carbon chain length from 4 to 18 . The FAS-I enzyme from the bacterium Mycobacterium tuberculosis prefers substrates with carbon chain length from 12 to 24 carbons.
Specify your search results
Word Map
- 1.3.1.9
- tuberculosis
- mycobacterium
- triclosan
- falciparum
- plasmodium
- isoniazid
- medicine
-
antitubercular
-
mycolic
-
antimycobacterial
- diazaborine
-
inh-resistant
-
pyrrolyl
-
triclosan-resistant
-
surflex-docking
-
comsia
- analysis
- pharmacology
- drug development
The enzyme appears in viruses and cellular organisms
Reaction Schemes
Synonyms
2-trans enoyl-acyl carrier protein reductase, 2-trans-enoyl-ACP (CoA) reductase, 2-trans-enoyl-ACP reductase, 2-trans-enoyl-ACP(CoA) reductase, BaENR, BMA0885, bsFabI, cold-shock induced protein 15, CSI15, EACP reductase, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
2-trans-enoyl-ACP (CoA) reductase
2-trans-enoyl-ACP reductase
2-trans-enoyl-ACP(CoA) reductase
BaENR
BMA0885
cold-shock induced protein 15
-
-
-
-
CSI15
-
-
-
-
EACP reductase
enoyl ACP reductase
enoyl acyl carrier protein reductase
enoyl acyl carrier protein reductase InhA
enoyl reductase
enoyl-ACP reductase
enoyl-ACP reductase I
enoyl-ACP reductase III
enoyl-acyl carrier protein reductase
enoyl-acyl carrier protein reductase I
enoyl-[acyl-carrier-protein] reductase
ENR
FabI
FabI-1
FabK
FabV
FAS-II enoyl reductase
FTT_0782
InhA
MtENR
MtInhA
NAD-dependent enoyl-ACP reductase
NADH-dependent enoyl reductase
NADH-dependent enoyl-ACP reductase
NADH-dependent enoyl-acyl carrier protein reductase
NADH-enoyl acyl carrier protein reductase
-
-
-
-
NADH-specific enoyl-ACP reductase
-
-
-
-
reductase, enoyl-[acyl carrier protein]
-
-
-
-
VEG241
-
-
-
-
vegetative protein 241
-
-
-
-
additional information
enoyl acyl carrier protein reductase
-
enoyl reductase
the enzyme is involved in Type II fatty acid synthesis
enoyl-ACP reductase
-
-
-
-
enoyl-ACP reductase
-
-
enoyl-acyl carrier protein reductase
-
-
ENR
-
-
FabI
-
-
InhA
-
-
InhA
-
NADH-dependent enoyl-ACP reductase
-
-
-
-
additional information
the enzyme is a member of the short chain dehydrogenase/reductase superfamily
additional information
the enzyme is a member of the short chain dehydrogenase/reductase superfamily
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
an acyl-[acyl-carrier protein] + NAD+ = a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+ = a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
an acyl-[acyl-carrier protein] + NAD+ = a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
detailed kinetic analysis of the sequential bi-bi mechanism with NADH binding first and NAD+ dissociating last. The catalytic tyrosine (Y235) and lysine (K244) residues are organized in the consensus Tyr-(Xaa)8-Lys motif. Both Y235 and K244 are involved in acid-base chemistry during substrate reduction
an acyl-[acyl-carrier protein] + NAD+ = a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
double displacement mechanism. In this mechanism, a catalytic event occurs after the binding of NADH to free enzyme, generating and releasing NAD+ into solution prior to the binding of crotonoyl-CoA to a modified form of the enzyme, followed by formation of butyryl-CoA and regeneration of free enzyme
-
an acyl-[acyl-carrier protein] + NAD+ = a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
sequential Bi Bi mechanism with NADH binding first and NAD+ dissociating last
an acyl-[acyl-carrier protein] + NAD+ = a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
detailed kinetic analysis of the sequential bi-bi mechanism with NADH binding first and NAD+ dissociating last. The catalytic tyrosine (Y235) and lysine (K244) residues are organized in the consensus Tyr-(Xaa)8-Lys motif. Both Y235 and K244 are involved in acid-base chemistry during substrate reduction
-
-
an acyl-[acyl-carrier protein] + NAD+ = a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
sequential Bi Bi mechanism with NADH binding first and NAD+ dissociating last
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
oxidation
redox reaction
-
-
-
-
reduction
oxidation
-
-
-
-
reduction
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
BRENDA
MetaCyc
(5Z)-dodecenoate biosynthesis I, (5Z)-dodecenoate biosynthesis II, 8-amino-7-oxononanoate biosynthesis I, 8-amino-7-oxononanoate biosynthesis IV, anteiso-branched-chain fatty acid biosynthesis, cis-vaccenate biosynthesis, even iso-branched-chain fatty acid biosynthesis, fatty acid elongation -- saturated, gondoate biosynthesis (anaerobic), mycolate biosynthesis, odd iso-branched-chain fatty acid biosynthesis, oleate biosynthesis IV (anaerobic), palmitate biosynthesis II (type II fatty acid synthase), palmitoleate biosynthesis I (from (5Z)-dodec-5-enoate), stearate biosynthesis II (bacteria and plants), streptorubin B biosynthesis
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
acyl-[acyl-carrier protein]:NAD+ oxidoreductase
The enzyme catalyses an essential step in fatty acid biosynthesis, the reduction of the 2,3-double bond in enoyl-acyl-[acyl-carrier-protein] derivatives of the elongating fatty acid moiety. The enzyme from the bacterium Escherichia coli accepts substrates with carbon chain length from 4 to 18 [3]. The FAS-I enzyme from the bacterium Mycobacterium tuberculosis prefers substrates with carbon chain length from 12 to 24 carbons.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
37251-08-4
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
(2E)-but-2-enoyl-[acyl carrier protein] + NADH + H+
butanoyl-[acyl-carrier protein] + NAD+
-
-
-
?
2-butylidene-cyclopentanone + NADH + H+
2-butyl-cyclopentanone + NAD+
-
81% conversion
-
-
?
2-butylidene-cyclopentanone + NADPH + H+
2-butyl-cyclopentanone + NADP+
-
-
-
-
?
2-dodecenoyl-[acyl-carrier protein] + NADH
dodecanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
2-hetpylidene-cyclopentanone + NADH + H+
2-heptylcyclopentanone + NAD+
-
63% conversion
-
-
?
2-hetpylidene-cyclopentanone + NADPH + H+
2-heptylcyclopentanone + NADP+
-
82% conversion
-
-
?
2-hexadecenoyl-[acyl-carrier protein] + NADH
hexadecanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
2-hexylidene-cyclopentanone + NADH + H+
2-hexylcyclopentanone + NAD+
-
61% conversion
-
-
?
2-hexylidene-cyclopentanone + NADPH + H+
2-hexylcyclopentanone + NADP+
-
67% conversion
-
-
?
2-pentylidene-cyclopentanone + NADH + H+
2-pentyl-cyclopentanone + NAD+
-
100% conversion
-
-
?
2-pentylidene-cyclopentanone + NADPH + H+
2-pentyl-cyclopentanone + NADP+
-
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
crotonyl-N-acetyl-cysteamine + NADH
butyryl-N-acetyl-cysteamine + NAD+
-
-
-
-
?
S-((2E)-oct-2-enoyl)-N-acetylcysteamine + NADH + H+
S-octanoyl-N-acetylcysteamine + NAD+
-
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
trans-2-decenoyl-[acyl-carrier protein] + NADH + H+
decanoyl-[acyl-carrier protein] + NAD+
-
-
-
?
trans-2-dodecenoyl-[acyl-carrier protein] + NADH
dodecanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-octenoyl-N-acetylcysteamine + NADH
octanoyl-N-acetylcysteamine + NAD+
-
-
-
?
trans-but-2-enoyl-[acyl-carrier protein] + NADH
butanoyl-[acyl-carrrier-protein] + NAD+
-
highly selective for NADH
-
-
?
trans-but-2-enoyl-[acyl-carrier protein] + NADH + H+
butanoyl-[acyl-carrier protein] + NAD+
-
-
-
r
(2E)-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
2-decenoyl-[acyl-carrier protein] + NADH
decanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
2-decenoyl-[acyl-carrier protein] + NADH
decanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
2-hexenoyl-[acyl-carrier protein] + NADH
hexanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
2-hexenoyl-[acyl-carrier protein] + NADH
hexanoyl-[acyl-carrier protein] + NAD+
-
fast reduction
-
-
?
2-octenoyl-[acyl-carrier protein] + NADH
octanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
2-octenoyl-[acyl-carrier protein] + NADH
octanoyl-[acyl-carrier protein] + NAD+
-
fast reduction
-
-
?
2-trans-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
-
?
2-trans-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
r
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
r
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
crotonyl-CoA + NAD+
butyryl-CoA + NADH + H+
A0A348A0U3
activity assay
-
-
?
crotonyl-CoA + NADH + H+
butyryl-CoA + NAD+
-
-
-
?
crotonyl-CoA + NADH + H+
butyryl-CoA + NAD+
-
-
-
-
?
crotonyl-CoA + NADH + H+
butyryl-CoA + NAD+
-
-
-
-
?
crotonyl-CoA + NADH + H+
butyryl-CoA + NAD+
-
activity assay
-
-
?
crotonyl-CoA + NADPH + H+
butyryl-CoA + NADP+
-
the native enzyme shows very weak activity with NADPH
-
-
?
crotonyl-[acyl-carrier protein] + NAD+
? + NADH + H+
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
ir
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
activity is 5.9fold higher than with crotonyl-CoA
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH
butyryl-[acyl-carrier protein] + NAD+
-
-
-
-
?
crotonyl-[acyl-carrier protein] + NADH + H+
butyryl-[acyl-carrier protein] + NAD+
-
-
-
-
r
crotonyl-[acyl-carrier protein] + NADH + H+
butyryl-[acyl-carrier protein] + NAD+
-
-
-
?
crotonyl-[acyl-carrier-protein] + NADH + H+
butyryl-[acyl-carrier-protein] + NAD+
-
-
-
?
crotonyl-[acyl-carrier-protein] + NADH + H+
butyryl-[acyl-carrier-protein] + NAD+
-
-
-
?
enoyl esters of acyl-carrier protein + NADH
?
-
lipid biosynthesis in plants
-
-
?
enoyl esters of acyl-carrier protein + NADH
?
-
last reductive step in fatty acid biosynthesis
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-decenoyl-CoA + NADH
decanoyl-CoA + NAD+
-
-
-
?
trans-2-decenoyl-CoA + NADH + H+
decanoyl-CoA + NAD+
-
-
-
?
trans-2-decenoyl-CoA + NADH + H+
decanoyl-CoA + NAD+
-
-
-
?
trans-2-decenoyl-CoA + NADH + H+
decanoyl-CoA + NAD+
-
-
-
?
trans-2-decenoyl-CoA + NADH + H+
decanoyl-CoA + NAD+
-
-
-
?
trans-2-decenoyl-[acyl-carrier protein] + NADH
decanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-decenoyl-[acyl-carrier protein] + NADH
decanoyl-[acyl-carrier protein] + NAD+
-
syn addition via 2Re, 3Si attack on double bond
-
-
?
trans-2-decenoyl-[acyl-carrier protein] + NADH
decanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-decenoyl-[acyl-carrier protein] + NADH
decanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
pre-steady state kinetics and equilibrium data of 2-trans-dodecenoyl-CoA substrate binding to InhA. The results indicate both positive homotropic cooperativity upon substrate binding to InhA, and a bimolecular association process followed by a slow isomerization of the enzyme-substrate binary complex
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
trans-2-dodecenoyl-CoA + NADH + H+
dodecanoyl-CoA + NAD+
-
-
-
?
trans-2-dodecenoyl-[acyl-carrier protein] + NADH
dodecanoyl-ACP + NAD+
-
-
-
-
?
trans-2-dodecenoyl-[acyl-carrier protein] + NADH
dodecanoyl-ACP + NAD+
-
-
-
-
?
trans-2-enoyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-enoyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
?
trans-2-enoyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-hexadecenoyl-CoA + NADH + H+
hexadecanoyl-CoA + NAD+
-
-
-
?
trans-2-hexadecenoyl-CoA + NADH + H+
hexadecanoyl-CoA + NAD+
-
-
-
?
trans-2-hexadecenoyl-CoA + NADH + H+
hexadecanoyl-CoA + NAD+
-
-
-
?
trans-2-hexadecenoyl-CoA + NADH + H+
hexadecanoyl-CoA + NAD+
-
-
-
?
trans-2-octenoyl-CoA + NADH + H+
octanoyl-CoA + NAD+
-
-
-
?
trans-2-octenoyl-CoA + NADH + H+
octanoyl-CoA + NAD+
-
-
-
?
trans-2-octenoyl-CoA + NADH + H+
octanoyl-CoA + NAD+
-
-
-
?
trans-but-2-enoyl-[acyl-carrier protein] + NADH
butanoyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-but-2-enoyl-[acyl-carrier protein] + NADH
butanoyl-[acyl-carrier protein] + NAD+
-
-
-
?
additional information
?
-
-
the final step of chain elongation in the bacterial fatty acid biosynthesis is the reduction of enoyl-ACP to an acyl-ACP, catalyzed by enoyl-ACP reductase
-
-
?
additional information
?
-
-
key enzyme in type II fatty-acid synthases that catalyzes the last step in each elongation cycle
-
-
?
additional information
?
-
key enzyme in type II fatty-acid synthases that catalyzes the last step in each elongation cycle
-
-
?
additional information
?
-
reduction of carbon-carbon double bond
-
-
?
additional information
?
-
enzyme is active with substrates of all fatty acid chain lengths
-
-
?
additional information
?
-
enzyme is active with substrates of all fatty acid chain lengths
-
-
?
additional information
?
-
activity measurement using NAD+ cofactor and substrate 2-dodecenoyl-CoA
-
-
?
additional information
?
-
activity measurement using NAD+ cofactor and substrate 2-dodecenoyl-CoA
-
-
?
additional information
?
-
catalyzes the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism
-
-
?
additional information
?
-
catalyzes the NADH-dependent reduction of 2-trans-dodecenoyl-CoA via a sequential Bi Bi mechanism
-
-
?
additional information
?
-
-
enoyl [acyl-carrier-protein] I uses NADH, whereas enoyl [acyl-carrier-protein] II uses NADPH
-
-
?
additional information
?
-
the recombinant ENR expressed in bacteria is only able to oxidize NADH, but unable to transfer the electron to enoyl-CoA, possibly due to the inappropriate folding of ENR expressed in bacteria
-
-
?
additional information
?
-
-
substrate specificity: acyl chain length C4-C16
-
-
?
additional information
?
-
activity detection via measurement of NADPH production by reduction of crotonoyl-CoA
-
-
?
additional information
?
-
activity detection via measurement of NADPH production by reduction of crotonoyl-CoA
-
-
?
additional information
?
-
activity detection using trans-2-dodecenyl-CoA and NADH as substrate and cofactor
-
-
?
additional information
?
-
activity detection using trans-2-dodecenyl-CoA and NADH as substrate and cofactor
-
-
?
additional information
?
-
-
activity detection via measurement of NADPH production by reduction of crotonoyl-CoA
-
-
?
additional information
?
-
-
no reduction of 3-decenoyl-[acyl-carrier-protein]
-
-
?
additional information
?
-
-
substrate specificity: acyl chain length C4-C16
-
-
?
additional information
?
-
-
FabK catalyzes the reduction of enoyl-ACPs with the concomitant oxidation of NADH
-
-
?
additional information
?
-
FabK catalyzes the reduction of enoyl-ACPs with the concomitant oxidation of NADH
-
-
?
additional information
?
-
-
activity measurement by reduction of the trans-2-octenoyl N-acetylcysteamine as substrate and NADH as cofactor
-
-
?
additional information
?
-
-
activity measurement by reduction of the trans-2-octenoyl N-acetylcysteamine as substrate and NADH as cofactor
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
an acyl-[acyl-carrier protein] + NAD+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
acyl-[acyl-carrier protein] + NAD+
trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
r
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
r
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
an acyl-[acyl-carrier protein] + NAD+
a trans-2,3-dehydroacyl-[acyl-carrier protein] + NADH + H+
-
-
-
?
enoyl esters of acyl-carrier protein + NADH
?
-
lipid biosynthesis in plants
-
-
?
enoyl esters of acyl-carrier protein + NADH
?
-
last reductive step in fatty acid biosynthesis
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2,3-dehydracyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-enoyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
trans-2-enoyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
?
trans-2-enoyl-[acyl-carrier protein] + NADH + H+
acyl-[acyl-carrier protein] + NAD+
-
-
-
-
?
additional information
?
-
-
the final step of chain elongation in the bacterial fatty acid biosynthesis is the reduction of enoyl-ACP to an acyl-ACP, catalyzed by enoyl-ACP reductase
-
-
?
additional information
?
-
-
key enzyme in type II fatty-acid synthases that catalyzes the last step in each elongation cycle
-
-
?
additional information
?
-
key enzyme in type II fatty-acid synthases that catalyzes the last step in each elongation cycle
-
-
?
additional information
?
-
-
FabK catalyzes the reduction of enoyl-ACPs with the concomitant oxidation of NADH
-
-
?
additional information
?
-
FabK catalyzes the reduction of enoyl-ACPs with the concomitant oxidation of NADH
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
NADH
-
-
NADH
-
-
NADH
although very flexible, in the wild-type enzyme/NADH complex, the NADH molecule keeps its extended conformation firmly bound to the binding site of the enzyme
NADH
while NADH binding to wild-type InhA is hyperbolic, the InhA mutants bind the cofactor with positive cooperativity, suggesting that the mutations permit access to a second conformational state of the protein
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Cs+
-
activation by univalent cations in descending order, NH4+, Rb+, Cs+, K+, and Na+
K+
-
activation by univalent cations in descending order, NH4+, Rb+, Cs+, K+, and Na+
Na+
-
activation by univalent cations in descending order, NH4+, Rb+, Cs+, K+, and Na+
Rb+
-
activation by univalent cations in descending order, NH4+, Rb+, Cs+, K+, and Na+
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1H-indol-5-yl)[4-[(4-methylphenyl)(phenyl)methyl]piperazin-1-yl]methanone
0.015 mM, 74% inhibition
(2E)-3-(1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]prop-2-enamide
(2E)-3-pyren-1-yl-1-[4-(1H-triaziren-1-yl)phenyl]prop-2-en-1-one
-
45% residual activity at 0.05 mM
(2E)-3-[4-(benzyloxy)phenyl]-2-cyano-N-(6-methylpyridin-2-yl)prop-2-enamide
-
-
(2E)-3-[6-(acetylamino)pyridin-3-yl]-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]prop-2-enamide
-
(2E)-N-(1H-indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide
-
-
(2E)-N-(3-methoxy-2-propoxybenzyl)-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-(3-methoxy-2-propoxybenzyl)-N-methyl-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-methyl-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(3-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-1,2,3,4,5,6-hexahydropyrido[2,3-b][1,5]diazocin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzofuran-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide
-
-
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1-benzothiophen-2-yl)methyl]-3-[3-(2-morpholin-4-ylethyl)-2-oxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidin-6-yl]prop-2-enamide
(2E)-N-methyl-N-[(3-methyl-1H-indol-2-yl)methyl]-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(1'-methyl-2-oxo-1,4-dihydro-2H-spiro[1,8-naphthyridine-3,4'-piperidin]-6-yl)prop-2-enamide
(2E)-N-[(5-fluoro-3-methyl-1-benzothiophen-2-yl)methyl]-N-methyl-3-(4-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-b][1,4]diazepin-8-yl)prop-2-enamide
(2E,4E)-N-[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]hexa-2,4-dienamide
-
(2E,4E)-N-[4-(2,4-dichlorophenoxy)-3-hydroxyphenyl]hexa-2,4-dienamide
-
(2S,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
-
-
(2S,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
-
-
(3aR,4S,6aR)-3,3a,4,6a-tetrahydro-2H-cyclopenta[b]furan-4,5-diyldimethanol
-
-
(4-(9H-fluoren-9-yl) piperazin-1-yl)-(4-methylbenzyl)-methanone
0.015 mM, 99% inhibition
(4-(9H-fluoren-9-yl)piperazin-1-yl) (2,5-difluorophenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (2-fluorophenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (3-fluorophenyl)methanone
uncompetitive versus NADH, competitive versus trans-2-dodecenoyl-CoA
(4-(9H-Fluoren-9-yl)piperazin-1-yl) (3-tolyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-chlorophenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-fluorophenyl)methanone
uncompetitive versus NADH, competitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-methoxyphenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (4-tolyl)methanone
uncompetitive versus NADH, competitive versus trans-2-dodecenoyl-CoA
(4-(9H-fluoren-9-yl)piperazin-1-yl) (phenyl)methanone
uncompetitive versus NADH, noncompetitive versus trans-2-dodecenoyl-CoA
(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-(1H-indole-5-carbonyl)-methanone
0.015 mM, 84% inhibition
(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-(4-methylbenzyl)-methanone
0.015 mM, 83% inhibition
(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-benzyl-methanone
0.015 mM, 81% inhibition
(4-methylphenyl)[4-[(4-methylphenyl)(phenyl)methyl]piperazin-1-yl]methanone
0.015 mM, 77% inhibition
(4S)-1-(2,4-dimethylphenyl)-4-(3-{4-[(propan-2-yl)oxy]phenyl}-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one
-
-
(4S)-1-(3,4-dimethylphenyl)-4-(3-{4-[(propan-2-yl)oxy]phenyl}-1,2,4-oxadiazol-5-yl)pyrrolidin-2-one
-
-
(5Z)-3-(3-chlorophenyl)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(3-chlorophenyl)-5-[[5-(4-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(3-fluorophenyl)-5-(furan-2-ylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-fluorophenyl)-5-[(3-hydroxyphenyl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-methoxyphenyl)-5-(phenylmethylidene)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-methoxyphenyl)-5-[(4-methoxyphenyl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-(4-methoxyphenyl)-5-[[4-(1-methylethyl)phenyl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-[3-chloro-4-(2-methylprop-1-en-1-yl)phenyl]-5-[(5,6-dihydroxy-1,6-dihydropyridazin-3-yl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-3-[4-(diethylamino)phenyl]-5-[(4-methoxyphenyl)methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-(anthracen-9-ylmethylidene)-3-(4-methoxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(2,4-dichlorophenyl)methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3,4-dihydroxyphenyl)methylidene]-3-phenyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3,5-dichloro-4-hydroxyphenyl)methylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3-hydroxy-5-methoxyphenyl)methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(3-hydroxyphenyl)methylidene]-3-phenyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(4-hydroxy-3-methoxyphenyl)methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(4-methoxynaphthalen-1-yl)methylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(5,6-dihydroxy-1,6-dihydropyridazin-3-yl)methylidene]-2-thioxo-3-(3,4,5-trimethylcyclohex-1-en-1-yl)-1,3-thiazolidin-4-one
-
-
(5Z)-5-[(5,6-dihydroxy-1,6-dihydropyridazin-3-yl)methylidene]-3-(7-ethenyl-2,3-dihydro-1H-inden-5-yl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[4-(diethylamino)-2-hydroxyphenyl]methylidene]-3-ethyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-3-(4-hydroxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[4-(dimethylamino)phenyl]methylidene]-3-(4-methoxyphenyl)-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(2,3-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(2,5-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(2-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3,4-dichlorophenyl)furan-2-yl]methylidene]-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3,5-dichlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-2-thioxo-1,3-thiazolidin-4-one
-
-
(5Z)-5-[[5-(3-chlorophenyl)furan-2-yl]methylidene]-3-methyl-2-thioxo-1,3-thiazolidin-4-one
-
-
(E)-1-benzyl-2-methyl-3-[2-(pyridin-3-yl)vinyl]-4-pyridone
-
IC50: higher than 0.100 mM
(E)-N-(1,2-dimethyl-1-H-indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetra hydro-1,8-naphthyridin-3-yl)acrylamide
-
(E)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)-N-(1,2,7-trimethyl-1H-indol-3-ylmethyl)acrylamide
-
0.00007 mM, 50% inhibition
(E)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphtyridin-3-yl)-N-(1,2,7-trimethyl-1H-indol-3-ylmethyl)acrylamide
-
0.00002 mM, 50% inhibition
(E)-N-methyl-N-(1,2-dimethyl-1H-indol-3-ylmethyl)-N-methyl-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(E)-N-methyl-N-(1-methyl-1H-indol-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(E)-N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(E)-N-methyl-N-(2-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
(RS)-1-hydroxy-1-[3-(octadecyloxy)-phenyl]-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one
-
28% inhibition at 0.03 mM, IC50 for growth of Mycobacterium tuberculosis is 0.012 mM
(RS)-1-[3-(dodecylsulfanyl)phenyl]-1-hydroxy-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one
-
15% inhibition at 0.03 mM, IC50 for growth of Mycobacterium tuberculosis is 0.0065 mM
1-(3,4-dichlorobenzyl)-5,6-dimethyl-1H-benzimidazole
compound has significant antibacterial activity against both Gram-positive and Gram-negative bacterial pathogens
1-(3-chlorocyclohexyl)-4-[(2-fluorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3,4-dichlorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3,4-dimethylphenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3-chlorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(3-methylphenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(4-fluorophenyl)carbonyl]piperazine
-
1-(3-chlorocyclohexyl)-4-[(4-methylphenyl)carbonyl]piperazine
-
1-(4-bromophenyl)-3-(dibenzo[b,d]furan-3-ylamino)propan-1-one
-
47% residual activity at 0.05 mM
1-(4-methyl-1,3-thiazol-2-yl)-1-(5-[[6-(morpholin-4-yl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-(5-[[6-(piperidin-1-yl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-(5-[[6-(trifluoromethyl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-[5-[(1-methyl-1H-1,2,3-triazol-4-yl)amino]-1,3,4-thiadiazol-2-yl]ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-[5-[(pyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]ethan-1-ol
-
-
1-(4-methyl-1,3-thiazol-2-yl)-1-[5-[(pyrimidin-2-yl)amino]-1,3,4-thiadiazol-2-yl]ethan-1-ol
-
-
1-(5-[[5-bromo-6-(trifluoromethyl)pyridin-2-yl]amino]-1,3,4-thiadiazol-2-yl)-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-(9H-fluoren-9-yl)-4-[(4-methylphenyl)carbonyl]piperazine
-
1-(cyclohexylmethyl)-3-(2,6-dichlorobenzyl)-2-methylpyridin-4(1H)-one
-
-
1-benzyl-2-methyl-3-[2-(pyridin-3-yl)ethyl]-4-pyridone
-
IC50: higher than 0.100 mM
1-benzyl-4-[3-(9H-carbazol-9-yl)propoxy]pyridin-2(1H)-one
-
less than 30% inhibition at 0.1 mM
1-bicyclo[2.2.1]hept-2-yl-N-biphenyl-3-yl-5-oxopyrrolidine-3-carboxamide
-
1-butyl-5-(4-chloro-2-methylphenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cycloheptyl-N-(2'-hydroxy-1,1':3',1''-terphenyl-4'-yl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-4-(2,3-dihydro-1H-indol-1-ylcarbonyl)pyrrolidin-2-one
-
1-cyclohexyl-4-([4-[(4-fluorophenyl)(phenyl)methyl]piperazin-1-yl]carbonyl)pyrrolidin-2-one
-
1-cyclohexyl-4-([4-[(4-methylphenyl)(phenyl)methyl]piperazin-1-yl]carbonyl)pyrrolidin-2-one
-
1-cyclohexyl-5-oxo-N-[3-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2'-hydroxy-1,1':3',1''-terphenyl-5'-yl)-5-oxopyrrolidine-3-carboxamide
-
-
1-cyclohexyl-N-(2,4-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(2-methyl-4-nitrophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-difluorophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-dimethylphenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3,5-diphenyl-4-hydroxyl)phenyl-5-oxopyrrolidine-3-carboxamide
best inhibitor of the sreening with an IC50: 62 nanoM
1-cyclohexyl-N-(3-methylphenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(3-nitrophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(4-iodophenyl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-(9-ethyl-9H-carbazol-2-yl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-9H-fluoren-4-yl-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-[(2'-hydroxy-1,1':3',1''-terphenyl-5'-yl)methyl]-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-[3-(1-methylethyl)phenyl]-5-oxopyrrolidine-3-carboxamide
-
1-cyclohexyl-N-[3-methoxy-5-(trifluoromethyl)phenyl]-5-oxopyrrolidine-3-carboxamide
-
1-cyclooctyl-N-(2'-hydroxy-1,1':3',1''-terphenyl-4'-yl)-5-oxopyrrolidine-3-carboxamide
-
1-cyclopropyl-5-(2,3-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cyclopropyl-5-(2,4-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cyclopropyl-5-(2,4-dimethylphenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-cyclopropyl-5-(2,6-dichlorophenoxy)-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
1-ethoxy-1-oxopropan-2-yl 5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoate
-
1-[(2H-1,3-benzodioxol-5-yl)methyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[(3,4-dichlorophenyl)methyl]-5,6-dimethyl-1H-benzimidazole
-
1-[(3,4-dimethoxyphenyl)methyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[(3,4-dimethylphenyl)carbonyl]-4-[3-(trifluoromethyl)cyclohexyl]piperazine
-
1-[(3-chlorophenyl)carbonyl]-4-(cyclohexylmethyl)piperidine
-
1-[(3-methylphenyl)carbonyl]-4-(4-nitrocyclohexyl)piperazine
-
1-[(4-methoxy-3-methylphenyl)methyl]-1,5,6,7-tetrahydroindeno[5,6-d]imidazole
-
1-[(4-methoxy-3-methylphenyl)methyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[(4-methylphenyl)carbonyl]-4-[3-(trifluoromethyl)cyclohexyl]piperazine
-
1-[1-(3,4-dichlorophenyl)ethyl]-1,5,6,7-tetrahydroindeno[5,6-d]imidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-5,6,7,8-tetrahydro-1H-naphtho[2,3-d]imidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-5,6-dimethyl-1H-benzimidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-5,7-dihydro-1H-furo[3,4-f]benzimidazole
-
1-[1-(3,4-dichlorophenyl)ethyl]-6,6-dimethyl-1,5,6,7-tetrahydroindeno[5,6-d]imidazole
-
1-[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]-2-phenylethane-1,2-dione
-
-
1-[4-(2,4-dichlorophenoxy)-3-hydroxyphenyl]-2-phenylethan-1-one
-
-
1-[4-[4-(4-chloro-2-hydroxyphenoxy)phenyl]piperazin-1-yl]ethan-1-one
-
25% inhibition 0.001 mM
1-[5-(3-bromo-4-fluoroanilino)-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-(4-chloro-2-hydroxyphenoxy)thiophen-2-yl]propan-1-one
-
75% inhibition 0.001 mM
1-[5-[(1-methyl-1H-pyrazol-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(1-methyl-1H-pyrazol-4-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(2-methoxypyridin-4-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(2-methylpyridin-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-bromo-6-methylpyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-bromopyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-fluoropyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(5-methylpyridin-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-bromopyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-cyclopropylpyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-fluoropyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-methoxypyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-methylpyridin-2-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[5-[(6-methylpyridin-3-yl)amino]-1,3,4-thiadiazol-2-yl]-1-(4-methyl-1,3-thiazol-2-yl)ethan-1-ol
-
-
1-[9-[4-(1H-indol-5-ylcarbonyl)piperazin-1-yl]-9H-fluoren-1-yl]ethanone
-
1-[bis(4-fluorophenyl)methyl]-4-(phenylcarbonyl)piperazine
-
1-[bis(4-fluorophenyl)methyl]-4-[(4-methylphenyl)carbonyl]piperazine
-
2,4-dichloro-N-(2-[[2-oxo-2-(phenylamino)ethyl]sulfanyl]-1,3-benzothiazol-6-yl)benzamide
-
49% residual activity at 0.05 mM
2-(2'-amino-4'-chloro-phenoxy)-5-chloro-phenol
-
inhibits the parasite growth, uncompetitive inhibition kinetics with crotonoyl-CoA and competitive with NADH
2-(2,4-dichlorophenoxy)-5-(hexylamino)phenol
-
73% inhibition at 1 mM
2-(2,4-dichlorophenoxy)-5-chlorophenol
triclosan, dissociation constant of the inhibitor from the enzyme-NAD+ product complex: 7.0 pM
2-(2,4-dichlorophenoxy)-5-[(1H-1,2,3-triazol-1-yl)methyl]phenol
-
97% inhibition at 1 mM
2-(2,4-dichlorophenoxy)-5-[5-(trimethylsilyl)-1,2-oxazol-3-yl]phenol
-
complete inhibition at 1 mM
2-(2-amino-4-chlorophenoxy)-5-chlorophenol
IC50 for Plasmodium falciparum in culture 0.0084 mM
2-(2-chloro-4-fluorophenyl)-N-(4-((3,5-dimethyl-1H-pyrazol-1-yl)-methyl)phenyl)acetamide
-
2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(5-nitrothiazol-2-yl)acetamide
-
2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide
-
2-(2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(4-[[(2,3-dihydro-1-benzofuran-6-ylmethyl)amino]methyl]-2-hydroxyphenoxy)-5-methylbenzonitrile
-
predicted inhibitor, based on in-silico screening
2-(5-chlorothiophen-2-yl)-N-[2-(1,2,3,4-tetrahydronaphthalen-1-yl)ethyl]quinoline-4-carboxamide
-
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(2-chloro-5-(trifluoromethyl)phenyl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(5-nitrothiazol-2-yl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(furan-2-ylmethyl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(6-chloro-2-methyl-4-oxoquinazolin-3(4H)-yl)-N-phenylacetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(2-chloro-5-(trifluoromethyl)phenyl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(5-nitrothiazol-2-yl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(furan-2-ylmethyl)acetamide
-
2-(6-chloro-4-oxoquinazolin-3(4H)-yl)-N-(thiophen-2-ylmethyl)acetamide
-
2-(dimethylamino)ethyl 3-[(5Z)-5-[(2,4-dichlorophenyl)methylidene]-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]propanoate
-
-
2-(dimethylamino)ethyl 6-[(5Z)-4-oxo-5-(phenylmethylidene)-2-thioxo-1,3-thiazolidin-3-yl]hexanoate
-
-
2-(ethanesulfonyl)-6-[2-[(E)-(hydroxyimino)methyl]-4-(trifluoromethyl)phenoxy]-2,3,1-benzodiazaborinin-1(2H)-ol
-
2-(ethanesulfonyl)-7-[2-[(Z)-(hydroxyimino)methyl]-4-(trifluoromethyl)phenoxy]-2,3,1-benzodiazaborinin-1(2H)-ol
diazaborine, in vitro bactericidal activity against replicating bacteria active against several drug-resistant clinical isolates. AN12855 binds to and inhibits the substrate-binding site of InhA in a cofactor-independent manner. It shows good drug exposure after i.v. and oral delivery, with 53% oral bioavailability. Delivered orally, AN12855 exhibits dose-dependent efficacy in both an acute and chronic murine model of tuberculosis infection. AN12855 is a promising candidate for the development of new antitubercular agents
2-decyl-1-methyl-5-(4-nitrophenoxy)pyridin-4(1H)-one
competitive inhibition
2-[(2-fluorophenyl)methyl]-N-[(1S)-1-(2-methyl-1,3-thiazol-4-yl)ethyl]-1,3-benzoxazole-5-carboxamide
-
-
2-[(3-chlorophenyl)sulfanyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)quinoline-4-carboxamide
-
-
2-[(6-ethoxy-1,3-benzothiazol-2-yl)sulfanyl]-N-(4-methylphenyl)acetamide
-
25% residual activity at 0.05 mM
2-[2-(dimethylamino)-4-sulfanylphenoxy]-5-[[(2-phenylethyl)amino]methyl]phenol
-
predicted inhibitor, based on in-silico screening
2-[4-(2,4-dinitrophenyl)-1H-pyrazol-1-yl]-4-(trifluoromethyl)pyrimidine
-
-
2-[4-({[(2,3-dihydro-1-benzofuran-6-yl)methyl]amino}methyl)-2-hydroxyphenoxy]-5-methylbenzonitrile
2-[[4-amino-5-(3,4-dichlorophenyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-N-naphthalen-2-ylacetamide
-
3% residual activity at 0.05 mM
2-[[4-amino-5-(4-chlorophenyl)-4H-1,2,4-triazol-3-yl]sulfanyl]-N-[4-bromo-2-(1-methylethyl)phenyl]acetamide
-
52% residual activity at 0.05 mM
2-[[6-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1,3-benzothiazol-2-yl]sulfanyl]-N-(4-fluorophenyl)acetamide
-
20% residual activity at 0.05 mM
2-{4-[(4-benzyl-1H-1,2,3-triazol-1-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
2-{4-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
2-{4-[(5-benzyl-1,2-oxazol-3-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
2-{4-[(5-butyl-1,2-oxazol-3-yl)methyl]-2-chlorophenoxy}-5-chlorophenol
-
-
3-(2,6-dichlorobenzyl)-2-methyl-1-(2-methyl-2-[[3-(trifluoromethyl)benzyl]sulfanyl]propyl)pyridin-4(1H)-one
-
-
3-(4-(4-chloro-2-hydroxyphenoxy)phenyl)-7-hydroxy-2H-chromen-2-one
-
3-(4-chloro-2-hydroxyphenoxy)-7-hydroxy-4-methyl-2H-chromen-2-one
-
3-(4-methoxyphenyl)-N-(6-phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)propanamide
-
-
3-bromo-N-(4-fluorobenzyl)-1-benzothiophene-2-carboxamide
-
competitive kinetics with cofactor NADH and uncompetitive kinetics with the substrate crotonyl-CoA
3-bromo-N-[4-(trifluoromethyl)benzyl]-1-benzothiophene-2-carboxamide
-
competitive kinetics with cofactor NADH and uncompetitive kinetics with the substrate crotonyl-CoA
3-hydroxy-4-phenoxybenzaldehyde
IC50 for Plasmodium falciparum in culture 0.077 mM
3-[(4-methylcyclohexyl)sulfamoyl]-N-(4-methylphenyl)benzamide
-
49% residual activity at 0.05 mM
3-[2-(3-fluoro-4-methoxyphenyl)-2-oxoethoxy]-6H-benzo[c]chromen-6-one
-
9% residual activity at 0.05 mM
3-[2-(4-bromophenyl)-2-oxoethoxy]-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one
-
53% residual activity at 0.05 mM
3-[3-(2-hydroxy-4-propylphenoxy)phenyl]acrylic acid methylester
A0A348A0U3
-
3-[3-(2-hydroxy-4-propylphenoxy)phenyl]propionic acid methylester
A0A348A0U3
-
3-[5-[(Z)-[4-oxo-2-thioxo-3-[3-(trifluoromethyl)phenyl]-1,3-thiazolidin-5-ylidene]methyl]furan-2-yl]benzoic acid
-
-
4-(2,4-dichlorophenoxy)-3-hydroxybenzaldehyde
IC50 for Plasmodium falciparum in culture 0.021 mM
4-(4-chloro-2-hydroxyphenoxy)-1-(4-methylphenylsulphonamido)benzene
A0A348A0U3
-
4-(cyclohexylmethyl)-1-[(2-fluorophenyl)carbonyl]piperidine
-
4-(cyclohexylmethyl)-1-[(3-methylphenyl)carbonyl]piperidine
-
4-(cyclohexylmethyl)-1-[(4-methylphenyl)carbonyl]piperidine
-
4-([4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]carbonyl)-1-cyclohexylpyrrolidin-2-one
-
4-([4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]carbonyl)-1-cyclohexylpyrrolidin-2-one
-
4-([[1-(2-chlorobenzyl)-2-oxo-1,2-dihydropyridin-4-yl]oxy]methyl)benzonitrile
-
-
4-bromo-N-(4-chlorophenyl)-3-(phenylsulfamoyl)benzamide
-
46% residual activity at 0.05 mM
4-bromo-N-[2-(3,4-dimethoxyphenyl)-1,3-benzoxazol-5-yl]benzamide
-
17% residual activity at 0.05 mM
4-bromo-N-[4-(trifluoromethyl)phenyl]benzamide
-
49% residual activity at 0.05 mM
4-decyl-1-[(4-nitrophenyl)methyl]pyridin-2(1H)-one
noncompetitive inhibition
4-hydroxy-1-(4-hydroxybenzyl)pyridin-2(1H)-one
-
less than 30% inhibition at 0.1 mM
4-hydroxy-1-(4-methoxybenzyl)pyridin-2(1H)-one
-
less than 30% inhibition at 0.1 mM
4-phenoxybenzamide adenine dinucleotide
NAD analogue which mimics isoniazid-NAD adduct
4-[(3'-methoxy[1,1'-biphenyl]-3-yl)carbamoyl]-1-(3-methylbut-2-en-1-yl)piperidin-1-ium
-
-
4-[(Z)-[3-(4-methoxyphenyl)-4-oxo-2-thioxo-1,3-thiazolidin-5-ylidene]methyl]benzaldehyde
-
-
4-[2-[(3-cyano-4,6-dithiophen-2-ylpyridin-2-yl)sulfanyl]ethyl]benzoic acid
-
-
4-[3-(1H-benzotriazol-1-yl)propoxy]-1-(2-chlorobenzyl)pyridin-2(1H)-one
-
-
4-[4-[(benzylamino)methyl]-2-hydroxyphenoxy]-3-chlorobenzonitrile
-
predicted inhibitor, based on in-silico screening
4-[5-chloro-2-(4-chloro-2-hydroxyphenoxy)phenyl]amino-4-oxobutanoic acid
-
-
4-[5-chloro-2-(4-chloro-2-methoxyphenoxy)phenyl]amino-4-oxobutanoic acid
-
-
4-[[1-hydroxy-2-(methanesulfonyl)-1,2-dihydro-2,3,1-benzodiazaborinin-7-yl]oxy]benzonitrile
-
4-{[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl}-3-chlorobenzoic acid
-
4-{[4-(benzyloxy)-2-oxopyridin-1(2H)-yl]methyl}-3-chlorobenzonitrile
-
5,11-dimethyl-8H-[2,3,1]benzodiazaborinino[2',1':5,6][1,3,5,2,6]oxadiazadiborinino[2,3-a][2,3,1]benzodiazaborinin-8-one
-
5-(2,3-dichlorophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,3-dichlorophenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,3-dichlorophenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dichlorophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,4-dichlorophenoxy)-2-(phenoxymethyl)-1-phenylpyridin-4(1H)-one
-
-
5-(2,4-dichlorophenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dichlorophenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dimethylphenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,4-dimethylphenoxy)-2-(phenoxymethyl)-1-phenylpyridin-4(1H)-one
-
-
5-(2,4-dimethylphenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,4-dimethylphenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,6-dichlorophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2,6-dichlorophenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2,6-dichlorophenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(2-chloro-3-nitrophenoxy)-1-cyclopropyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2-chloro-3-nitrophenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(2-chlorophenoxy)-2-methoxypyridine 1-oxide
-
less than 30% inhibition at 0.1 mM
5-(4-chloro-2-hydroxyphenoxy)-N-(5-methyl-1,2-oxazol-3-yl)furan-2-carboxamide
-
90% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)-N-methylfuran-2-carboxamide
-
46% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)-N-[4-(prop-1-en-2-yl)piperazin-1-yl]furan-2-carboxamide
-
45% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)furan-2-carboxylic acid
-
79% inhibition 0.001 mM
5-(4-chloro-2-hydroxyphenoxy)thiophene-2-carboxylic acid
-
48% inhibition 0.001 mM
5-(4-chloro-2-methylphenoxy)-1-cyclopropyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(4-chloro-2-methylphenoxy)-1-methyl-2-(phenoxymethyl)pyridin-4(1H)-one
-
-
5-(4-chloro-2-methylphenoxy)-2-(phenoxymethyl)-1-phenylpyridin-4(1H)-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(1E)-3-methylbut-1-en-1-yl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(1E)-pent-1-en-1-yl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(1H-pyrrol-2-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(furan-2-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(furan-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(pyridin-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(thiophen-2-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-(thiophen-3-yl)ethenyl]-4H-pyran-4-one
-
-
5-(4-chloro-2-methylphenoxy)-2-[(E)-2-phenylethenyl]-4H-pyran-4-one
-
-
5-(benzylamino)-2-(2,4-dichlorophenoxy)phenol
-
25% inhibition at 1 mM
5-(cyclohexylamino)-2-(2,4-dichlorophenoxy)phenol
-
12.5% inhibition at 1 mM
5-([4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]carbonyl)-1H-indole
-
5-([[2-(4-chlorophenyl)ethyl]amino]methyl)-2-[2-(dimethylamino)-4-ethylphenoxy]phenol
-
predicted inhibitor, based on in-silico screening
5-([[2-(4-chlorophenyl)ethyl]amino]methyl)-2-[2-ethyl-4-(sulfanylmethyl)phenoxy]phenol
-
predicted inhibitor, based on in-silico screening
5-({[(2,3-dihydro-1-benzofuran-6-yl)methyl]amino}methyl)-2-[2-methyl-4-(methylamino)phenoxy]phenol
5-benzyl-N-{[3-chloro-4-(4-chloro-2-hydroxyphenoxy)phenyl]methyl}-1,2-oxazole-3-carboxamide
-
-
5-chloro-2-(2,4-dichloro-phenoxy)phenol
-
trivial name triclosan, slow, tight-binding inhibitor
5-chloro-2-(4'-chloro-2'-nitro-phenoxy)-phenol
-
inhibits the parasite growth
5-chloro-2-(4-chloro-2-[1-[(4-chlorobenzyl)(methyl)amino]-1-methylethyl]phenoxy)phenol
-
-
5-chloro-2-(4-chloro-2-[1-[(4-chlorobenzyl)amino]-1-methylethyl]phenoxy)phenol
-
-
5-chloro-2-(4-chloro-2-[[(2,3-dihydro-1-benzofuran-5-ylmethyl)amino]methyl]phenoxy)phenol
-
-
5-chloro-2-(4-chloro-2-[[(4-chlorobenzyl)(methyl)amino]methyl]phenoxy)phenol
-
-
5-chloro-2-[(5-[[4-(prop-1-en-2-yl)piperazin-1-yl]methyl]thiophen-2-yl)oxy]phenol
-
73% inhibition 0.001 mM
5-chloro-2-[2-chloro-4-(trifluoromethyl)phenoxy]phenol
-
95% inhibition 0.001 mM
5-chloro-2-[4-(4-methylpiperazin-1-yl)phenoxy]phenol
-
81% inhibition 0.001 mM
5-chloro-2-[4-(piperidine-1-sulfonyl)phenoxy]phenol
-
78% inhibition 0.001 mM
5-chloro-2-[4-(pyrrolidine-1-sulfonyl)phenoxy]phenol
-
81% inhibition 0.001 mM
5-chloro-2-[4-chloro-2-[(4-phenylpiperazin-1-yl)methyl]phenoxy]phenol
-
-
5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]phenoxy]phenol
-
32% inhibition 0.001 mM
5-chloro-2-{2-chloro-4-[(1H-1,2,3-triazol-1-yl)methyl]phenoxy}phenol
-
-
5-chloro-2-{2-chloro-4-[(hexylamino)methyl]phenoxy}phenol
-
38% inhibition at 1 mM
5-cyclohexyl-2-[2-(methylamino)-4-propylphenoxy]phenol
-
predicted inhibitor, based on in-silico screening
5-methyl-N-[(1E)-(3-nitrophenyl)methylidene]-4-phenyl-1,3-thiazol-2-amine
-
-